<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03917719</url>
  </required_header>
  <id_info>
    <org_study_id>CAT-1004-302</org_study_id>
    <nct_id>NCT03917719</nct_id>
  </id_info>
  <brief_title>An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy</brief_title>
  <acronym>GalaxyDMD</acronym>
  <official_title>An Open-Label Extension Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catabasis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catabasis Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The GalaxyDMD study is a global Phase 3, open-label, treatment extension study to evaluate
      the safety, tolerability, and durability of effect in long-term dosing of edasalonexent in
      pediatric patients with a genetically confirmed diagnosis of DMD. Patients who completed
      CAT-1004-201 or CAT-1004-301 or siblings of these boys from 4-12 years of age (up to 13th
      birthday) will be enrolled.

      Edasalonexent is an orally administered small molecule that inhibits NF-kB, which is a key
      link between loss of dystrophin and disease pathology and plays a fundamental role in the
      initiation and progression of skeletal and cardiac muscle disease in DMD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study includes a 104-week open-label treatment period with edasalonexent. Patients who
      completed CAT-1004-201 or CAT-1004-301 and eligible siblings of these boys will be enrolled
      in this trial.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 14, 2019</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of long-term treatment with edasalonexent measured by number of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)</measure>
    <time_frame>104 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Durability of effects of edasalonexent on physical function as measured by the North Star Ambulatory Assessment (NSAA)</measure>
    <time_frame>104 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durability of effects of edasalonexent on physical function as measured by the 10-meter walk/run test</measure>
    <time_frame>104 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durability of effects of edasalonexent on physical function as measured by the time to stand from supine</measure>
    <time_frame>104 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durability of effects of edasalonexent on physical function as measured by the 4-stair climb</measure>
    <time_frame>104 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Edasalonexent 100mg/kg/day. Capsules taken by mouth three times per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edasalonexent</intervention_name>
    <description>100 mg/kg/day</description>
    <arm_group_label>Dose 1</arm_group_label>
    <other_name>Edasa</other_name>
    <other_name>CAT-1004</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For Patients who Completed CAT-1004-201 or CAT-1004-301:

        Inclusion Criteria:

          -  Written consent/assent by patient and/or legal guardian as per regional and/or
             Institutional Review Board (IRB)/Independent Ethics Committee (IEC) requirements

          -  Completion of either CAT-1004-201 or CAT-1004-301

        Exclusion Criteria:

          -  In the Investigator's opinion, unwilling or unable for any reason to complete all
             study assessments and laboratory tests and comply with scheduled visits,
             administration of drug, and all other study procedures

        For Siblings of Patients who Completed CAT-1004-201 or CAT-1004-301:

        Inclusion Criteria:

          -  Written consent/assent by patient and/or legal guardian as per regional and/or
             Institutional Review Board (IRB)/Independent Ethics Committee (IEC) requirements

          -  A sibling of a patient who completed either CAT-1004-201 or CAT-1004-301

          -  Diagnosis of DMD based on a clinical phenotype with increased serum creatine kinase
             (CK) and documentation of mutation(s) in the dystrophin gene known to be associated
             with a DMD phenotype

          -  Followed by a doctor or medical professional who coordinates Duchenne care on a
             regular basis and willingness to disclose patient's study participation with medical
             professionals

        Exclusion Criteria:

          -  Use of oral corticosteroids at screening; use of inhaled, intranasal, and topical
             corticosteroids is permitted

          -  Use of another investigational drug, idebenone, or dystrophin-focused therapy within 4
             weeks. Exception: Patients who are currently on or plan to initiate treatment with
             approved oligonucleotide exon-skipping therapies, and expected to continue treatment
             throughout the study, will be eligible

          -  Use of the following within 4 weeks prior to Day 1: immunosuppressive therapy,
             anticoagulants, cyclosporine, dihydroergotamine, ergotamine, fentanyl, alfentanil,
             pimozide, quinidine, sirolimus or tacrolimus

          -  Use of human growth hormone within 3 months prior to Day 1

          -  Other prior or ongoing significant medical conditions
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne M Donovan, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Catabasis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rare Disease Research, LLC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Children's Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kennedy Krieger Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Vegas Clinic</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shriners Hospital for Children</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Munich</name>
      <address>
        <city>Munich</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Silvia Children's Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Children's Hospital</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8AE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital (GOSH)</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 12, 2019</study_first_submitted>
  <study_first_submitted_qc>April 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Muscular Dystrophies</keyword>
  <keyword>Musculoskeletal Diseases</keyword>
  <keyword>Neuromuscular Diseases</keyword>
  <keyword>DMD</keyword>
  <keyword>dystrophin</keyword>
  <keyword>dystrophy</keyword>
  <keyword>Duchenne</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

